Anti-SARS-CoV-2 Vaccination in People with Multiple Sclerosis: Lessons Learnt a Year in

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2022 Nov 3

PMID 36325318

Authors

Maura Pugliatti

Hans-Peter Hartung

Celia Oreja-Guevara

Carlo Pozzilli

Laura Airas

Mona Alkhawajah

Nikolaos Grigoriadis

Melinda Magyari

Bart Van Wijmeersch

Magd Zakaria

Ralf Linker

Andrew Chan

Patrick Vermersch

Thomas Berger

Affiliations

Soon will be listed here.

Abstract

It has been over a year since people with multiple sclerosis (pwMS) have been receiving vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). With a negligible number of cases in which vaccination led to a relapse or new onset MS, experts around the world agree that the potential consequences of COVID-19 in pwMS by far outweigh the risks of vaccination. This article reviews the currently available types of anti-SARS-CoV-2 vaccines and the immune responses they elicit in pwMS treated with different DMTs. Findings to date highlight the importance of vaccine timing in relation to DMT dosing to maximize protection, and of encouraging pwMS to get booster doses when offered.

Citing Articles

Is there still hesitancy towards SARS-CoV-2 vaccination among people with neurological disease- a survey of the NeuroCOVID-19 task force of the European Academy of Neurology.

Hochmeister S, Rakusa M, Moro E, Bereczki D, Cavallieri F, Fanciulli A Neurol Sci. 2025; .

PMID: 39903350 DOI: 10.1007/s10072-025-08017-w.

Clinical effectiveness of coronavirus disease 2019 vaccination in patients with multiple sclerosis stratified by disease-modifying treatment.

De Troyer M, Van Remoortel A, Van Schependom J, Faille L, Dhooghe M, Peeters G Eur J Neurol. 2024; 31(7):e16300.

PMID: 38641878 PMC: 11235867. DOI: 10.1111/ene.16300.

COVID-19 Vaccination and Disease Course in People with Multiple Sclerosis in Greece.

Bakirtzis C, Konstantinidou N, Stavropoulou De Lorenzo S, Moysiadis T, Boziki M, Grigoriadou E J Clin Med. 2023; 12(17).

PMID: 37685528 PMC: 10488265. DOI: 10.3390/jcm12175460.

Summary of Safety and Efficacy of COVID Vaccination in Patients with Multiple Sclerosis.

Pernicova E, Macounova P, Krsek M, Madar R Eur Neurol. 2023; 86(4):263-276.

PMID: 36871554 PMC: 10614228. DOI: 10.1159/000529982.

Safety of SARS-CoV2 vaccination and COVID-19 short-term outcome in pediatric acquired demyelinating disorders of central nervous system: A single center experience.

Monte G, Papetti L, Ferilli M, Ursitti F, Moavero R, Sforza G Front Immunol. 2023; 14:1106472.

PMID: 36761740 PMC: 9905148. DOI: 10.3389/fimmu.2023.1106472.

References

Ewer K, Barrett J, Belij-Rammerstorfer S, Sharpe H, Makinson R, Morter R . T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nat Med. 2020; 27(2):270-278. DOI: 10.1038/s41591-020-01194-5. View

Maniscalco G, Manzo V, Di Battista M, Salvatore S, Moreggia O, Scavone C . Severe Multiple Sclerosis Relapse After COVID-19 Vaccination: A Case Report. Front Neurol. 2021; 12:721502. PMC: 8382847. DOI: 10.3389/fneur.2021.721502. View

Moreira Jr E, Kitchin N, Xu X, Dychter S, Lockhart S, Gurtman A . Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine. N Engl J Med. 2022; 386(20):1910-1921. PMC: 9006787. DOI: 10.1056/NEJMoa2200674. View

Meyer M, Huang E, Yuzhakov O, Ramanathan P, Ciaramella G, Bukreyev A . Modified mRNA-Based Vaccines Elicit Robust Immune Responses and Protect Guinea Pigs From Ebola Virus Disease. J Infect Dis. 2017; 217(3):451-455. PMC: 5853918. DOI: 10.1093/infdis/jix592. View

Bar-Or A, Calkwood J, Chognot C, Evershed J, Fox E, Herman A . Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study. Neurology. 2020; 95(14):e1999-e2008. PMC: 7843152. DOI: 10.1212/WNL.0000000000010380. View

Heinz F, Stiasny K . Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action. NPJ Vaccines. 2021; 6(1):104. PMC: 8368295. DOI: 10.1038/s41541-021-00369-6. View

Capuano R, Donnarumma G, Bisecco A, Grimaldi E, Conte M, dAmbrosio A . Humoral response to SARS-CoV-2 mRNA vaccine in patients with multiple sclerosis treated with natalizumab. Ther Adv Neurol Disord. 2021; 14:17562864211038111. PMC: 8369851. DOI: 10.1177/17562864211038111. View

Ciampi E, Uribe-San-Martin R, Soler B, Garcia L, Guzman J, Pelayo C . Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with Multiple Sclerosis. Mult Scler Relat Disord. 2022; 59:103690. PMC: 8842089. DOI: 10.1016/j.msard.2022.103690. View

Greco R, Alexander T, Burman J, Papa N, de Vries-Bouwstra J, Farge D . Hematopoietic stem cell transplantation for autoimmune diseases in the time of COVID-19: EBMT guidelines and recommendations. Bone Marrow Transplant. 2021; 56(7):1493-1508. PMC: 8143059. DOI: 10.1038/s41409-021-01326-6. View

10.

Oster M, Shay D, Su J, Gee J, Creech C, Broder K . Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021. JAMA. 2022; 327(4):331-340. PMC: 8790664. DOI: 10.1001/jama.2021.24110. View

11.

Patel N, DSilva K, Hsu T, DiIorio M, Fu X, Cook C . Coronavirus Disease 2019 Outcomes Among Recipients of Anti-CD20 Monoclonal Antibodies for Immune-Mediated Diseases: A Comparative Cohort Study. ACR Open Rheumatol. 2021; 4(3):238-246. PMC: 8916578. DOI: 10.1002/acr2.11386. View

12.

Reyes S, Ramsay M, Ladhani S, Amirthalingam G, Singh N, Cores C . Protecting people with multiple sclerosis through vaccination. Pract Neurol. 2020; 20(6):435-445. DOI: 10.1136/practneurol-2020-002527. View

13.

Mailand M, Frederiksen J . Vaccines and multiple sclerosis: a systematic review. J Neurol. 2016; 264(6):1035-1050. DOI: 10.1007/s00415-016-8263-4. View

14.

Menni C, May A, Polidori L, Louca P, Wolf J, Capdevila J . COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study. Lancet Infect Dis. 2022; 22(7):1002-1010. PMC: 8993156. DOI: 10.1016/S1473-3099(22)00146-3. View

15.

Almendro-Vazquez P, Laguna-Goya R, Ruiz-Ruigomez M, Utrero-Rico A, Lalueza A, Maestro de la Calle G . Longitudinal dynamics of SARS-CoV-2-specific cellular and humoral immunity after natural infection or BNT162b2 vaccination. PLoS Pathog. 2021; 17(12):e1010211. PMC: 8757952. DOI: 10.1371/journal.ppat.1010211. View

16.

Badrawi N, Kumar N, Albastaki U . Post COVID-19 vaccination neuromyelitis optica spectrum disorder: Case report & MRI findings. Radiol Case Rep. 2021; 16(12):3864-3867. PMC: 8512112. DOI: 10.1016/j.radcr.2021.09.033. View

17.

Sormani M, Schiavetti I, Carmisciano L, Cordioli C, Filippi M, Radaelli M . COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context. Neurol Neuroimmunol Neuroinflamm. 2021; 9(1). PMC: 8579249. DOI: 10.1212/NXI.0000000000001105. View

18.

Bar-On Y, Goldberg Y, Mandel M, Bodenheimer O, Amir O, Freedman L . Protection by a Fourth Dose of BNT162b2 against Omicron in Israel. N Engl J Med. 2022; 386(18):1712-1720. PMC: 9006780. DOI: 10.1056/NEJMoa2201570. View

19.

Konig M, Torgauten H, Tran T, Holmoy T, Vaage J, Lund-Johansen F . Immunogenicity and Safety of a Third SARS-CoV-2 Vaccine Dose in Patients With Multiple Sclerosis and Weak Immune Response After COVID-19 Vaccination. JAMA Neurol. 2022; 79(3):307-309. PMC: 8787678. DOI: 10.1001/jamaneurol.2021.5109. View

20.

Achiron A, Mandel M, Dreyer-Alster S, Harari G, Magalashvili D, Sonis P . Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. Ther Adv Neurol Disord. 2021; 14:17562864211012835. PMC: 8072850. DOI: 10.1177/17562864211012835. View